• KOL
    • Hepatocellular Carcinoma
    • Jordi Bruix
    • Jordi Bruix: Influence Statistics

       Jordi Bruix

      Jordi Bruix

      Show email address

      BCLC group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS. CIBEREHD. University of Barcelona., Spain | Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Jordi Bruix:Expert Impact

      Concepts for whichJordi Bruixhas direct influence:Hepatocellular carcinoma,Liver transplantation,Hepatocellular carcinoma hcc,Patients hepatocellular carcinoma,Carcinoma hepatocellular,Patients hcc,Liver neoplasms,Surgical resection.

      Jordi Bruix:KOL impact

      Concepts related to the work of other authors for whichfor which Jordi Bruix has influence:Hepatocellular carcinoma,Liver transplantation,Hcc patients,Transarterial chemoembolization,Radiofrequency ablation,Chronic hepatitis,Portal hypertension.

      KOL Resume for Jordi Bruix

      Year
      2022

      BCLC group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS. CIBEREHD. University of Barcelona., Spain

      2021

      Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clinic, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain;, (J.C.);, (V.S.);, (M.S.-Z.);, (C.M.);, (E.S.);, (N.L.);, (G.I.);, (L.G.D.F.);, (S.M.-M.);, (A.F.);, (J.B.)

      Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28028 Madrid, Spain

      2020

      BCLC Group, Hospital Clinic-IDIBAPS, Barcelona, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.

      National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, “Instituto de Salud Carlos III”), San Sebastian, Spain

      2019

      Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.

      Barcelona Clinic Liver Cancer (BCLC) Group. Liver Unit, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Spain

      2018

      Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain

      BCLC Group, Liver Unit, University of Barcelona, Barcelona, Spanien

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Jordi Bruix is among the top experts in the world.
      Concept World rank
      peginterferon clinical event #1
      pegdems treatment #1
      hepatocellular carcinoma dialysis #1
      early hcc panel #1
      imaging lirads category #1
      advanced hcc atezo #1
      survival survival predictors #1
      variceal bleeding measurement #1
      abt263 sorafenib efficacy #1
      t300 tremelimumab #1
      regorafenib survival #1
      followup ethanol injection #1
      regorafenib alteration #1
      presence arterialphase enhancement #1
      gammaglutamyltranspeptidase bilirubin #1
      eobmr #1
      diagnóstico publication carcinoma #1
      baseline ferucarbotranenhanced imaging #1
      early dermatologic #1
      bclc5 cells #1
      hcc tumour burden #1
      nodules washout #1
      disida uptake #1
      resorce ttp #1
      7 csph #1
      pegifnα2b observation #1
      mfs f3 #1
      hcccc subgroup #1
      diagnostic accuracy eccemr #1
      actitest mfs #1
      patients f3 mfs #1
      intravenous somatostatin treatment #1
      screening programs analysis #1
      early hcc stage #1
      5 20mm #1
      biopsy baseline predictor #1
      arterial phase nodules #1
      hcc diagnostic imaging #1
      csph noncsph #1
      icc cirrhosis patients #1
      cases simulation model #1
      patients sorafenib discontinuation #1
      safety survival benefit #1
      f3 mfs retreatment #1
      hepatocellular carcinoma tamoxifen #1
      pattern tumor progression #1
      regorafenib hepatocellular carcinoma #1
      probability increased risk #1
      hcc patients diarrhea #1
      tumor uptake hcc #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Jordi Bruix

      KOL-Index: 23491

      BACKGROUND: Patients undergoing liver transplantation for hepatocellular carcinoma within the Milan criteria (single tumour

      Known for Milan Criteria | Hepatocellular Carcinoma | Liver Transplantation | Microvascular Invasion | 5year Survival
      KOL-Index: 22412

      BACKGROUND: There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation.

      METHODS: We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcinoma with a complete radiological response after surgical resection (n=900) or ...

      Known for Hepatocellular Carcinoma | Sorafenib Placebo | Local Ablation | Surgical Resection | Adjuvant Therapy
      KOL-Index: 20666

      BACKGROUND: There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment. We aimed to assess the efficacy and safety of regorafenib in patients with HCC who have progressed during sorafenib treatment.

      METHODS: In this randomised, double-blind, parallel-group, phase 3 trial done at 152 sites in 21 countries, adults with HCC who tolerated sorafenib (≥400 mg/day for ≥20 of last 28 days of treatment), progressed on ...

      Known for Sorafenib Treatment | Regorafenib Patients | 3 Trial | Hepatocellular Carcinoma | Hcc Liver Neoplasms
      KOL-Index: 17561

      BACKGROUND/AIMS: To investigate the impact of hepatitis B (HBV) and C (HCV) infections on hepatocellular carcinoma (HCC) in Europe.

      METHODS: Five hundred and three patients with HCC, from six liver centers, were included. All 503 sera and 80 liver samples were tested for HBV DNA and HCV RNA by polymerase chain reaction. GBV-C/HGV RNA was also tested in 57 sera.

      RESULTS: HBsAg and anti-HCV were detected in 19% and 40.1% of the patients, respectively. Serum and liver HBV DNA were detected ...

      Known for Hbv Hcv | Hepatocellular Carcinoma | Patients Hcc | Gbvc Hgv | Viral Human Humans
      KOL-Index: 17301

      PURPOSE: To evaluate the diagnostic accuracy of the Liver Imaging Reporting and Data System (LI-RADS) with magnetic resonance (MR) imaging for hepatic nodules 20 mm or smaller detected during ultrasonographic (US) surveillance in patients with cirrhosis.

      MATERIALS AND METHODS: Between November 2003 and January 2010, patients with cirrhosis with a newly US-detected solitary hepatic nodule 20 mm or smaller were included in this institutional ethics committee-approved study. All patients ...

      Known for 20 Mm | Liver Imaging Reporting | Lirads Category | Magnetic Resonance Imaging | Patients Nodules
      KOL-Index: 16901

      BACKGROUND & AIMS: Transarterial chemoembolization with doxorubicin-eluting beads (DC Bead®; DEB-TACE) is effective in patients with Barcelona clinic liver cancer stage B hepatocellular carcinoma (HCC). The multikinase inhibitor sorafenib enhances overall survival (OS) and time-to-tumor progression (TTP) in patients with advanced HCC. This exploratory phase II trial tested the efficacy and safety of DEB-TACE plus sorafenib in patients with intermediate stage HCC.

      METHODS: Patients with ...

      Known for Sorafenib Patients | Stage Hcc | Debtace Ttp | Eluting Beads | Tace Placebo
      KOL-Index: 16386

      BACKGROUND & AIMS: Sorafenib, an oral multikinase inhibitor, significantly prolonged overall survival (OS) vs. placebo in patients with unresectable hepatocellular carcinoma (HCC) in two phase III studies, SHARP (Sorafenib HCC Assessment Randomized Protocol) and Asia Pacific (AP). To assess prognostic factors for HCC and predictive factors of sorafenib benefit, we conducted a pooled exploratory analysis from these placebo-controlled phase III studies.

      METHODS: To identify potential ...

      Known for Sorafenib Benefit | Hepatocellular Carcinoma | Patients Hcc | Phase Iii | Hepatitis Virus
      KOL-Index: 15963

      BACKGROUND & AIMS: The RESORCE trial showed that regorafenib improves overall survival (OS) in patients with hepatocellular carcinoma progressing during sorafenib treatment (hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.50-0.78; p <0.0001). This exploratory analysis describes outcomes of sequential treatment with sorafenib followed by regorafenib.

      METHODS: In RESORCE, 573 patients were randomized 2:1 to regorafenib 160 mg/day or placebo for 3 weeks on/1 week off. Efficacy and ...

      Known for Sorafenib Regorafenib | Sequential Treatment | Resorce Trial | Patients Hepatocellular Carcinoma | Clinical Benefit
      KOL-Index: 15849

      BACKGROUND/AIMS: The influence of the infecting virus genotype on the progression of the underlying liver disease in patients with chronic hepatitis C virus (HCV) infection remains controversial. The aim of this study was to investigate the prevalence of HCV genotypes in Spanish patients with chronic HCV infection and to elucidate the relationship between the infecting genotype and the severity of the disease.

      METHODS: A cross-sectional, retrospective analysis of frequency distribution ...

      Known for Hcv Genotype | Hepatocellular Carcinoma | Patients Cirrhosis | Hepatitis Virus | Liver Disease
      KOL-Index: 15775

      A subset of patients with hepatocellular carcinoma (HCC) beyond Milan criteria might obtain acceptable survival outcomes after liver transplantation. Living donor liver transplantation (LDLT) has emerged as a feasible alternative to overcome the paucity of donors. In 2001, we started a protocol for LDLT in Child A-B patients with HCC fulfilling a set of criteria-the Barcelona Clinic Liver Cancer (BCLC) expanded criteria-that expanded the conventional indications of transplantation: 1 ...

      Known for Milan Criteria | Liver Transplantation | Hepatocellular Carcinoma | Barcelona Clinic | Living Donor
      KOL-Index: 15304

      BACKGROUND/AIMS: The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy. We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models.

      METHODS: Gene expression (qRT-PCR, oligonucleotide microarray), DNA copy number changes (SNP-array), methylation of tumor ...

      Known for Combined Sorafenib | Liver Neoplasms | Hepatocellular Carcinoma | Combination Rapamycin | Hcc Ras
      KOL-Index: 15070

      PURPOSE: Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, double-blind, randomized, placebo-controlled trial assessed brivanib in patients with HCC who had been treated with sorafenib.

      PATIENTS AND METHODS: ...

      Known for Sorafenib Patients | Hepatocellular Carcinoma | Brivanib Placebo | Progression Ttp | Phase Iii
      KOL-Index: 14771

      BACKGROUND AND AIMS: Conventional pathological analysis fails to achieve sufficient sensitivity and specificity for the diagnosis of hepatocellular carcinoma (HCC) in small nodules. Immunohistochemical staining for glypican 3 (GPC3), heat shock protein 70 (HSP70) and glutamine synthetase (GS) has been suggested to allow a confident diagnosis but no prospective study has established the diagnostic accuracy of this approach. The aim of this study is to assess prospectively the diagnostic ...

      Known for Glutamine Synthetase | Immunohistochemical Panel | Hepatocellular Carcinoma | Diagnosis Hcc | Heat Shock
      KOL-Index: 14362

      This study assesses the magnetic resonance (MR) features of intrahepatic cholangiocarcinoma (ICC) in patients with cirrhosis with specific analysis of the contrast enhancement pattern. Cholangiocarcinoma may show increased contrast uptake in the arterial phase, and, if washout in the delayed venous phase were to be detected, the noninvasive diagnostic criteria proposed in the American Association for the Study of Liver Diseases guidelines would be refuted. We reviewed the MR findings of ...

      Known for Magnetic Resonance | Hepatocellular Carcinoma | Contrast Washout | Delayed Phases | Icc Cirrhosis
      KOL-Index: 14030

      BACKGROUND: Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial.

      METHODS: We did a phase 3, randomised, double-blind, placebo-controlled study in 90 centres in Australia, the Americas, Europe, ...

      Known for Placebo Patients | Advanced Hepatocellular | Phase 3 | 2 Study | Survival Progression

      Key People For Hepatocellular Carcinoma

      Top KOLs in the world
      #1
      Jordi Bruix
      hepatocellular carcinoma liver transplantation patients hcc
      #2
      Josep María Llovet
      hepatocellular carcinoma advisory consultancy liver transplantation
      #3
      Vincenzo Mazzaferro
      hepatocellular carcinoma liver transplantation patients hcc
      #4
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #5
      Jacques Ferlay
      cancer incidence global burden latin america
      #6
      Hashem B EL‐SERAG
      united states hepatocellular carcinoma veterans affairs

      BCLC group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS. CIBEREHD. University of Barcelona., Spain | Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain | BCLC group. Liver Unit, Hospital Cl

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.